Cencora, Inc. (COR) stock

CORNYSEWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends September 30

Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 14/3022% above fair value

$349.38−0.50 (-0.14%)

Close on Nov 12, 2026Market cap $66.67BP/E 25.9Yield 0.63%

Cencora r&d expenses

Research and development expenses are spending on new products and technology.

Cencora has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is COR.

Revenue growth5.1% · median 7.5%

Gross margin4.0% · median 12.3%

Operating margin0.9% · median 2.5%

Net margin0.8% · median 1.6%

Advertisement
300 × 250

See a number that looks wrong?